The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
The upcoming portfolio of respiratory products aims to provide effective solutions for a range of respiratory conditions
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
Subscribe To Our Newsletter & Stay Updated
